This new agreement will use BioFocus’s high throughput screening expertise to discover compounds that ‘hit’ nuclear hormone receptors (NHRs).
Under the terms of the agreement, BioFocus will receive research fees that will ramp up as the programs progress, while Lilly will gain access to BioFocus’s screening and biology expertise.
“We are delighted to have initiated this new relationship with Lilly,” said Geoff McMillan, chief executive of BioFocus. “It is particularly pleasing that another top tier pharmaceutical company has chosen BioFocus as its drug discovery partner.”
The agreement with Lilly is just one of a number of partnerships BioFocus has forged with major pharmaceutical and biotechnology companies. Indeed, the company’s partners and main clients include Amgen, GlaxoSmithKline, Pfizer, Roche, and Millennium and it has provided services and/or products to 17 out of the top 20 pharmaceutical companies worldwide.